-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ZYNLONTA®: The First and Only CD19-Directed ADC For 3L DLBCL

Sponsor: ADC Therapeutics
Program: Product Theaters
Monday, December 12, 2022: 8:00 AM-9:00 AM
Hall J - Theater 4 (Ernest N. Morial Convention Center)
Joseph Camardo, MD, ADC Therapeutics, Inc.
No relevant conflicts of interest to declare.
This presentation is intended for U.S. based registered meeting attendees
See more of: Product Theaters